Purpose The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular lymphoma (FL) by using parameters which could not be retrospectively studied before, and by choosing progression-free survival (PFS) as principal end point. Patients and Methods Between January 2003 and May 2005, 1,093 patients with a newly diagnosed FL were registered and 942 individuals receiving antilymphoma therapy were selected as the study population. The variables we used for score definition were selected by means of bootstrap resampling procedures on 832 patients with complete data. Procedures to select the model that would minimize errors were also performed. Results After a median follow-up of 38 months, 261 events for PFS evaluation were recorded. beta 2-microglobulin higher than the upper limit of normal, longest diameter of the largest involved node longer than 6 cm, bone marrow involvement, hemoglobin level lower than 12 g/dL, and age older than 60 years were factors independently predictive for PFS. Using these variables, a prognostic model was devised to identify three groups at different levels of risk. The 3-year PFS rate was 91%, 69%, and 51% for patients at low, intermediate, and high risk, respectively (log-rank = 64.6; P < .00001). The 3-year survival rate was 99%, 96%, and 84% for patients at low, intermediate, and high risk, respectively (P < .0001). Conclusion Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy. J Clin Oncol 27:4555-4562. (C) 2009 by American Society of Clinical Oncology

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project / M., Federico; M., Bellei; L., Marcheselli; S., Luminari; A., Lopez Guillermo; U., Vitolo; B., Pro; S., Pileri; Pulsoni, Alessandro; P., Soubeyran; S., Cortelazzo; G., Martinelli; Martelli, Maurizio; L., Rigacci; L., Arcaini; F., Di Raimondo; F., Merli; E., Sabattini; P., Mclaughlin; P., Solal Celigny. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 27 (27):(2007), pp. 4555-4562. (Intervento presentato al convegno 43rd Annual Meeting of the American-Society-of-Clinical-Oncology tenutosi a Chicago, IL nel JUN 01-05, 2007).

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

PULSONI, Alessandro;MARTELLI, Maurizio;
2007

Abstract

Purpose The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular lymphoma (FL) by using parameters which could not be retrospectively studied before, and by choosing progression-free survival (PFS) as principal end point. Patients and Methods Between January 2003 and May 2005, 1,093 patients with a newly diagnosed FL were registered and 942 individuals receiving antilymphoma therapy were selected as the study population. The variables we used for score definition were selected by means of bootstrap resampling procedures on 832 patients with complete data. Procedures to select the model that would minimize errors were also performed. Results After a median follow-up of 38 months, 261 events for PFS evaluation were recorded. beta 2-microglobulin higher than the upper limit of normal, longest diameter of the largest involved node longer than 6 cm, bone marrow involvement, hemoglobin level lower than 12 g/dL, and age older than 60 years were factors independently predictive for PFS. Using these variables, a prognostic model was devised to identify three groups at different levels of risk. The 3-year PFS rate was 91%, 69%, and 51% for patients at low, intermediate, and high risk, respectively (log-rank = 64.6; P < .00001). The 3-year survival rate was 99%, 96%, and 84% for patients at low, intermediate, and high risk, respectively (P < .0001). Conclusion Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy. J Clin Oncol 27:4555-4562. (C) 2009 by American Society of Clinical Oncology
2007
43rd Annual Meeting of the American-Society-of-Clinical-Oncology
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project / M., Federico; M., Bellei; L., Marcheselli; S., Luminari; A., Lopez Guillermo; U., Vitolo; B., Pro; S., Pileri; Pulsoni, Alessandro; P., Soubeyran; S., Cortelazzo; G., Martinelli; Martelli, Maurizio; L., Rigacci; L., Arcaini; F., Di Raimondo; F., Merli; E., Sabattini; P., Mclaughlin; P., Solal Celigny. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 27 (27):(2007), pp. 4555-4562. (Intervento presentato al convegno 43rd Annual Meeting of the American-Society-of-Clinical-Oncology tenutosi a Chicago, IL nel JUN 01-05, 2007).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/485075
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact